Type of menopause, patterns of hormone therapy use, and hot flashes

2006 ◽  
Vol 85 (5) ◽  
pp. 1432-1440 ◽  
Author(s):  
Lisa Gallicchio ◽  
Maura K. Whiteman ◽  
Dragana Tomic ◽  
Kimberly P. Miller ◽  
Patricia Langenberg ◽  
...  
Keyword(s):  
2008 ◽  
Vol 04 (01) ◽  
pp. 108
Author(s):  
Collins John

More than 50% of women going through the menopause experience hot flashes, which may cause sleep disturbances and lethargy. The symptoms are due to estrogen deficiency, which may also cause urogenital atrophy and vaginal dryness. In 25% of women, symptoms of the menopause are severe enough to seek relief. In women who do not undergo treatment, the proportion with hot flashes decreases to about 30% within three years.1


2009 ◽  
Vol 116 (3) ◽  
pp. 521-527 ◽  
Author(s):  
Cynthia R. Osborne ◽  
Anita Duncan ◽  
Scot Sedlacek ◽  
Devchand Paul ◽  
Frankie Holmes ◽  
...  

2010 ◽  
Vol 23 (6) ◽  
pp. 540-547 ◽  
Author(s):  
C. Brock Woodis

Nearly 50 million women each year are projected to reach menopause by 2030. Many of these women will experience vasomotor symptoms such as night sweats and hot flashes as they enter the menopausal transition. Up until the release of the findings of the Women’s Health Initiative (WHI) studies, women were frequently prescribed hormone therapy (HT) to alleviate bothersome and sometimes debilitating menopausal symptoms as well as to prevent osteoporosis and coronary heart disease (CHD). Although the WHI studies were the first large, randomized, controlled trials that contradicted what was historically believed about the benefits of HT in postmenopausal women, important limitations including baseline demographics of WHI participants and investigation of only one HT strength/dosage form exist. HT may be a reasonable pharmacotherapy option for the management of menopausal symptoms following complete patient evaluation by experienced clinicians. Updated recommendations addressing management of menopausal symptoms, a new HT product containing the spironolactone-analogue drospirenone (DRSP), and discontinuation methods of HT are also discussed in this review.


Author(s):  
Kalinkina O.B.

Levonorgestrel-containing intrauterine system Mirena refers to the first-line therapy of heavy menstrual bleeding (OMC) according to the recommendations of different countries. The efficacy, acceptability, and quality of life of women using Mirena are similar to those in the surgical treatment of abnormal uterine bleeding, including endometrial ablation and hysterectomy. The clinical case presented in this study of the management of a patient with heavy menstrual bleeding allowed us to demonstrate the effectiveness of the levonorgestrel-containing Mirena intrauterine system in OMC. The patient was observed in the consultative polyclinic of the V. D. Seredavin State Medical University. At the initial treatment, she complained of heavy menstruation, decreased performance, weight gain, and periodic increases in blood pressure. After a comprehensive clinical examination, taking into account heavy menstruation, a decrease in the quality of life, as well as the need for contraception, the introduction of the Mirena IUD was recommended. A year after the introduction of the IUD, the patient had amenorrhea. 5 years after the introduction of the Mirena IUD, the patient developed hot flashes, increased sweating, vaginal dryness, mood swings, sleep disorders, accompanied by an increase in FSH levels. The intrauterine system was removed and a new IUD - Mirena-was installed as a component of menopausal hormone therapy. After 2 months from the beginning of therapy, the complaints were completely stopped, the state of health is satisfactory, dryness in the vagina does not bother. Thus, the use of the LNG – IUD Mirena was effective for the relief of heavy menstrual bleeding, in addition, in women of this age group, it is possible to continue using the levonorgestrel-containing intrauterine system Mirena as a component of menopausal hormone therapy.


Sign in / Sign up

Export Citation Format

Share Document